KELER TIBOR 4

What Happened Tibor Keler, Executive Vice President & Chief Scientific Officer of Celldex Therapeutics (CLDX), received a grant of 115,000 derivative securities (option award) on June 25, 2026. The Form 4 reports an acquisition price of $0.00 (award/derivative), meaning this was a compensation grant rather than an open-market purchase or sale. No immediate cash value or strike price is disclosed in the filing.

Key Details

• Transaction date: 2026-06-25; Form 4 filed: 2026-06-29 (timely).
• Transaction type/code: A (award/grant of derivative securities).
• Quantity: 115,000 options (acquired at $0.00 as reported).
• Vesting (per filing footnote): 25% vests on June 25, 2027; remaining 75% vests quarterly in equal amounts over the subsequent 12 quarters (i.e., over the following 3 years).
• Shares/ownership after transaction: Not specified in the provided Form 4.
• Footnotes: F1 = grant under the 2021 Omnibus Equity Incentive Plan; F2 = vesting schedule described above.
• Filing timeliness: Filed within the expected window (no late filing indicated).

Context This was an equity compensation award (stock options) — a common way companies compensate executives. Because this is a grant, it does not represent an immediate purchase or sale of shares and does not indicate that any shares were sold or acquired on the open market. Vesting is multi-year, so any potential value depends on Celldex’s future stock performance and the option strike price (not disclosed here). Such awards are routine for executive retention and incentive purposes; they should be interpreted as part of compensation, not a direct market sentiment signal.